Synlogic (SYBX) Received its Third Buy in a Row

After H.C. Wainwright and Piper Sandler gave Synlogic (NASDAQ: SYBX) a Buy rating last month, the company received another Buy, this time from Chardan Capital. Analyst Keay Nakae reiterated a Buy rating on Synlogic today and set a price target of $10.00. The company's shares closed last Monday at $3.71. According to TipRanks.com, Nakae is a 5-star analyst with an average return of 21.4% and a 48.0% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Emergent Biosolutions, and Kaleido Biosciences. Currently, the analyst consensus on Synlogic is a Strong Buy with an average price target of $10.75, implying a 205.4% upside from current levels. In a report issued on September 7, H.C. Wainwright also reiterated a Buy rating on the stock with a $9.00 price target. See today’s analyst top recommended stocks >> Based on Synlogic's latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $246K and GAAP net loss of $14.49 million. In comparison, last year the company earned revenue of $445K and had a GAAP net loss of $15.54 million. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Synlogic, Inc. is a clinical-stage biopharmaceutical company, which engages in drug discovery and development of synthetic biotic medicines. It focuses on SYNB1020 and SYNB1618, which are orally administered and target hyperammonemia and phenylketonuria. It also works on SYNB1891, an intratumorally administered which treats cancer. The company was founded by Jim Collins and Tim Lu on August 28, 2017, and is headquartered in Cambridge, MA. Read More on SYBX: Scorpio Tankers: Solid Future Catalysts in Place Brookline Capital Markets Thinks Syros Pharmaceuticals’ Stock is Going to Recover Keysight Technologies: A Bright Future Ahead Can Lucid Stock Clear Up? This Is What You Need to Know Restaurant Brands International: An Industry Underdog to Watch The post Synlogic (SYBX) Received its Third Buy in a Row appeared first on TipRanks Financial Blog.

After H.C. Wainwright and Piper Sandler gave Synlogic (NASDAQ: SYBX) a Buy rating last month, the company received another Buy, this time from Chardan Capital. Analyst Keay Nakae reiterated a Buy rating on Synlogic today and set a price target of $10.00. The company's shares closed last Monday at $3.71.

According to TipRanks.com, Nakae is a 5-star analyst with an average return of 21.4% and a 48.0% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Emergent Biosolutions, and Kaleido Biosciences.

Currently, the analyst consensus on Synlogic is a Strong Buy with an average price target of $10.75, implying a 205.4% upside from current levels. In a report issued on September 7, H.C. Wainwright also reiterated a Buy rating on the stock with a $9.00 price target.

Based on Synlogic's latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $246K and GAAP net loss of $14.49 million. In comparison, last year the company earned revenue of $445K and had a GAAP net loss of $15.54 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Synlogic, Inc. is a clinical-stage biopharmaceutical company, which engages in drug discovery and development of synthetic biotic medicines. It focuses on SYNB1020 and SYNB1618, which are orally administered and target hyperammonemia and phenylketonuria. It also works on SYNB1891, an intratumorally administered which treats cancer. The company was founded by Jim Collins and Tim Lu on August 28, 2017, and is headquartered in Cambridge, MA.

Read More on SYBX:

  • Scorpio Tankers: Solid Future Catalysts in Place
  • Brookline Capital Markets Thinks Syros Pharmaceuticals’ Stock is Going to Recover
  • Keysight Technologies: A Bright Future Ahead
  • Can Lucid Stock Clear Up? This Is What You Need to Know
  • Restaurant Brands International: An Industry Underdog to Watch

The post Synlogic (SYBX) Received its Third Buy in a Row appeared first on TipRanks Financial Blog.

Source : Tip Ranks More   

What's Your Reaction?

like
0
dislike
0
love
0
funny
0
angry
0
sad
0
wow
0

Next Article

Brown & Brown Snaps up AGIS Network, Gremesco

Brown & Brown (BRO) has acquired all the assets of AGIS Network, Inc. AGIS Network is an employee benefits enrolment firm that facilitates technology-driven resources, and long-term care benefits options for Read More... The post Brown & Brown Snaps up AGIS Network, Gremesco appeared first on TipRanks Financial Blog.

Brown & Brown Snaps up AGIS Network, Gremesco

Brown & Brown () has acquired all the assets of AGIS Network, Inc.

AGIS Network is an employee benefits enrolment firm that facilitates technology-driven resources, and long-term care benefits options for large employer groups, governmental agencies, and individual consumers.

The addition of AGIS Network will enhance Brown & Brown’s capabilities to better serve the long-term care marketplace. (See BRO stock charts on TipRanks)

Paul Rogers, SVP for Brown & Brown National Employee Benefits, commented, “The AGIS acquisition is an excellent complement to our existing value proposition that focuses on specialization to deliver extraordinary value to our employee benefits customers.”

Brown & Brown also announced that its subsidiary, Bridge Specialty Group, has acquired all the assets of Gremesco.

Gremesco is a wholesale insurance broker offering property and casualty insurance products and services through retail agents in New Jersey and New York.

The financial terms of both deals have been kept under wraps.

Last month, Wolfe Research analyst Michael Zaremski initiated coverage of Brown & Brown with a Hold rating, and a price target of $61 (8.6% upside potential).

Consensus among analysts is a Moderate Buy, based on two Buys and four Holds. The average Brown & Brown price target of $58.83 implies 4.7% upside potential to current levels.

TipRanks data shows that financial blogger opinions are 100% Bullish on BRO, compared to a sector average of 73%.

Related News:
Carrier Global Corporation To Snap up BrokerBay
Nokia to Launch 5G Network in Indonesia with Indosat Ooredoo
Infosys Bags 5-year Deal with Frost Bank to Launch New Mortgage Loans

The post Brown & Brown Snaps up AGIS Network, Gremesco appeared first on TipRanks Financial Blog.

Source : Tip Ranks More   

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.